Skip to content
Screener

Medpace Holdings, Inc. MEDP Total Liabilities & Equity

Total Liabilities & Equity at other companies

Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
$113.17B+11.8%
Labcorp Holdings logo
Labcorp HoldingsLH
$18.53B+2.6%
IQVIA logo
IQVIAIQV
$29.88B+4.4%
Fortrea Holdings Inc. logo
Fortrea Holdings Inc.FTRE
$2.71B-4.2%
Oric Pharmaceuticals, Inc. logo
Oric Pharmaceuticals, Inc.ORIC
$436.76M+79.8%
Lifecore Biomedical, Inc. logo
Lifecore Biomedical, Inc.LFCR
$229.5M

Other financials

Income statement

See full
Revenue$707.3M+17.2%
Operating income$146.8M+16.2%
Net income$121.4M+34.5%
EPS (diluted)$4.25+37.1%

Balance sheet

See full
Cash & equivalents$502.7M+985%
Total debt$144.1M-3.8%
Total equity$433.9M+152%
Total assets$2.1B+30.9%

Cash flow

See full
Operating cash flow$162.0M+9.1%
CapEx$23.9M+291%
Free cash flow$138.1M-3.0%

Valuation

See full
Market cap$16.41B+35.7%
Enterprise value$16.05B+31.6%
P/E33.4×+4.5×
P/S5.9×+0.5×

Profitability

See full
Operating margin21%-0.4pp
Net margin17.7%-1.1pp
FCF margin25.4%-0.6pp

Returns & leverage

See full
Return on equity162.2%+72.8pp
Debt / equity0.3×-0.5×
Current ratio0.7×+0.3×

Where this comes from

Reported directly by Medpace Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The source filing: Medpace Holdings, Inc.’s 10-Q, filed July 23, 2026.

Filed
Jul 23, 2026, 4:03 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001668397-26-000025
(Amounts in thousands, except share amounts)As of / June 30,2026As of / December 31,2025
Preferred stock - $0.01 par-value; 5,000,000 shares authorized; no shares issued and outstanding at June 30, 2026 and December 31, 2025
Common stock - $0.01 par-value; 250,000,000 shares authorized at June 30, 2026 and December 31, 2025; 27,910,605 and 28,370,780 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively279284
Treasury stock - 69,593 and 69,623 shares at June 30, 2026 and December 31, 2025, respectively(12,151)(12,156)
Additional paid-in capital964,183935,830
Accumulated deficit(511,368)(459,981)
Accumulated other comprehensive loss(7,082)(4,906)
Total shareholders’ equity433,861459,071
Total liabilities and shareholders’ equity$2,057,181$1,975,472

Item 1. Financial Statements (unaudited)

FAQ

What is Medpace Holdings, Inc.'s total liabilities & equity?
Medpace Holdings, Inc. (MEDP) reported total liabilities & equity of $2.06B in Q2 2026.
How has Medpace Holdings, Inc.'s total liabilities & equity changed year-over-year?
Medpace Holdings, Inc.'s total liabilities & equity increased by 30.9% year-over-year, from $1.57B to $2.06B.
What is the long-term trend for Medpace Holdings, Inc.'s total liabilities & equity?
Over 5 years (2020 to 2025), Medpace Holdings, Inc.'s total liabilities & equity has grown at a 7.3% compound annual growth rate (CAGR), from $1.39B to $1.98B.
What does total liabilities & equity mean?
Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.

Ask your AI about Medpace Holdings, Inc.'s total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude